Evercore Wealth Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Evercore Wealth Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-32,062	Closed	-$1.47M	–	902
2017 Q4	$1.47M	Hold	32,062	–	–	0.05%	161
2017 Q3	$1.44M	Hold	32,062	–	–	0.06%	158
2017 Q2	$958K	Buy	32,062 +2,000	+7%	+$49.4K	0.04%	184
2017 Q1	$667K	Buy	30,062 +8,000	+36%	+$172K	0.03%	223
2016 Q4	$416K	Hold	22,062	–	–	0.02%	268
2016 Q3	$662K	Buy	22,062 +3,125	+17%	+$97.2K	0.03%	218
2016 Q2	$728K	Hold	18,937	–	–	0.03%	199
2016 Q1	$721K	Buy	+18,937	New	+$660K	0.03%	203

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Evercore Wealth Management's JUNO Position: Q1 2018 in Review

Evercore Wealth Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 32,062 shares — an estimated $1.47M sold.

Evercore Wealth Management first reported a position in JUNO in Q1 2016 and held it in 8 quarters. The position peaked at $1.47M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Evercore Wealth Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Evercore Wealth Management sold 32,062 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $1.47M.
Evercore Wealth Management first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 8 quarters.
Evercore Wealth Management's Juno Therapeutics, Inc. position peaked at $1.47M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Evercore Wealth Management's 13F filing for Q1 2018, filed 15 May 2018.